The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
We estimated lifetime prevalence of psychedelic use (lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), mescaline, and peyote) by age category using data from a 2010 US population survey of 57,873 individuals aged 12 years and older. There were approximately 32 million lifetime psychedelic users in the US in 2010; including 17% of people aged 21 to 64 years (22% of males and 12% of females). Rate of lifetime psychedelic use was greatest among people aged 30 to 34 (total 20%, including 26% of males and 15% of females).
The classical serotonergic psychedelics, LSD (lysergic acid diethylamide), psilocybin (“magic mushrooms”), and mescaline (peyote and other cacti), have their main mechanism of action at the serotonin 2A receptor (5-HT2A), produce similar, often indistinguishable subjective effects, and elicit cross-tolerance1,2. The mechanisms of action, subjective effects, and risk profile of the classical serotonergic psychedelics distinguishes them from other drugs sometimes also labeled “hallucinogens”, such as entactogens, like methylenedioxymethamphetamine (MDMA; ecstasy) that act primarily at serotonin transporters, or dissociative anesthetics, like phencyclidine (PCP) or ketamine that act primarily at NMDA glutamate receptors1.
Prevalence data on psychedelic use in the US is often reported for LSD alone (ignoring psilocybin and mescaline), or for psychedelics grouped together with PCP (popular in the 1970s), MDMA (popular since the 1990s), and/or other “hallucinogens” (some older estimates of hallucinogen use even included cannabis, amphetamine, and cocaine as hallucinogenic drugs), or for use among teenagers but not adults. Here, we present estimated lifetime prevalence of psychedelic use by age category using data from a large US population survey.
We examined the estimated lifetime use of psychedelics by age based on 2010 data of the National Survey on Drug Use and Health (NSDUH). Results are presented for males and females separately. We counted participants as having any lifetime psychedelic use if they reported ever using LSD, psilocybin, mescaline, or peyote. The use of mescaline and peyote were combined into one category because mescaline is the active substance of the peyote cactus, but peyote use was also examined separately. Current age was only available as a categorical variable. This study was exempt from review by our Regional Committee for Medical Research Ethics because all data are available in the public domain without any identification of personal information.
The annual NSDUH survey provides estimates of substance use and mental health indicators from a randomly-selected sample representative of the US civilian non-institutionalized population aged 12 and older. The Substance Abuse and Mental Health Services Administration (SAMHSA) of the US Department of Health and Human Services is responsible for the NSDUH study design and methods of assessment. Trained interviewers met the randomly-selected participants in their homes, and participants listened to recorded questions via headphones and then entered their answers directly into a computer, providing a highly confidential and standardized setting. The response rate was approximately 78%. In addition, approximately 10% of participants were excluded from the public use data file, either because of excessive missing data on drug use or because they were excluded at random in order to increase anonymity. The total number of respondents in the public use file was 57,873. Detailed information on the sampling and data collection methods, including interview instructions and questionnaires, confidentiality and informed consent are available on the SAMHSA website (http://oas.samhsa.gov/nsduh.htm).
Estimates were calculated using the online Survey Documentation Analysis from the Inter-university Consortium for Political and Social Research (http://dx.doi.org/10.3886/ICPSR32722.v3). Calculations of estimated population percentages and extrapolated total numbers of psychedelic users in the US took into account the weights provided with the NSDUH public use data file. Variance estimates took into account the complex sample design of the NSDUH survey using Taylor series linearization. Respondents with missing data on psychedelic use (less than 1% of the respondents) were assumed to have no use.
An estimated 32 million (95% confidence interval (CI): 30 to 33 million) US residents in 2010 reported lifetime use of LSD (23 million, 95% CI: 22 to 25 million), psilocybin (21 million, 95% CI: 20 to 22 million), mescaline (11 million, 95% CI: 10 to 12 million), or peyote (6 million, 95% CI: 5 to 7 million).
Figure 1 shows the rate of lifetime psychedelic use in the US in 2010 by age category and gender. Lifetime rate of psychedelic use among people aged 50 to 64 years (the “baby boomer” generation) was similar to the rate among people aged 21 to 49 years. Among people aged 21 to 64 years, 17%, (95% CI: 15% to 18%) reported ever using LSD, psilocybin, or mescaline, including 22% (95% CI: 21% to 23%) of males and 12% (11% to 13%) of females. Prevalence of psychedelic use was low among people aged 65 and older (total 1.3%, 95% CI: 0.8% to 2.1%). Rate of lifetime psychedelic use was greatest among people aged 30 to 34 years (total 20%, 95% CI: 18% to 22%), with 26% (95% CI: 23% to 29%) of males and 15% (95% CI: 13% to 17%) of females.
Psychedelics continue to be widely used in the US. Common reasons given for using psychedelics include curiosity, mystical experiences, and introspection3. Rates of lifetime psychedelic use are greater in males than in females. Overall rates of lifetime psychedelic use are roughly the same among the “baby boomers” and younger adults. However, psilocybin was more common among younger adults, while LSD and mescaline or peyote were more common among older adults. Use of psilocybin mushrooms has increased since the 1970s in the US and worldwide, likely due to dissemination of simple home cultivation techniques, instructions on finding wild mushrooms, and information about effects and methods of psilocybin mushroom use4. This was a retrospective cross-sectional study. Self-reports of drug use behaviors could be influenced by memory errors and under-reporting; however, a 14-year longitudinal study reported good consistency over time in the reporting of lifetime LSD use5.
Open Peer Review
Current Referee Status:
Key to Referee Statuses
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservationsKey revisions are required to address specific details and make the paper fully scientifically sound
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Read more about the unique F1000Research publication and peer review model here.
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
- Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
- You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
- You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
- You work at the same institute as any of the authors.
- You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
- You are an Editor for the journal in which the article is published.
- You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
- You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
- You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.